Atrium Therapeutics, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Total Revenue | 19.6M | 859K |
| Cost of Goods Sold | 151K | 0 |
| Gross Profit | 19.5M | 859K |
| R&D Expenses | 16.7M | 18.5M |
| Operating Expenses | 36.8M | 48.9M |
| Operating Income | -17.3M | -48.0M |
| Other Income / Gains | 647K | 0 |
| Net Income | -16.6M | -48.1M |
| EPS (Diluted) | -0.97 | -1.70 |
| Reported Currency | USD | USD |
| Gross Profit Ratio | 0.992 | 1.00 |
| General And Administrative Expenses | 0 | 30.4M |
| Selling And Marketing Expenses | 0 | 0 |
| Selling General And Administrative Expenses | 20.1M | 30.4M |
| Other Expenses | 0 | 0 |
| Cost And Expenses | 36.9M | 48.9M |
| Interest Income | 0 | 0 |
| Interest Expense | 0 | 0 |
| Depreciation And Amortization | 151K | 122K |
| Ebitda | -16.5M | -47.9M |
| Ebitdaratio | -0.839 | -55.778 |
| Operating Income Ratio | -0.88 | -55.92 |
| Income Before Tax | -16.6M | -48.0M |
| Income Before Tax Ratio | -0.847 | -55.92 |
| Income Tax Expense | 0 | 34K |
| Net Income Ratio | -0.847 | -55.959 |
| Epsdiluted | -0.97 | -1.70 |
| Weighted Average Shs Out | 17.1M | 17.1M |
| Weighted Average Shs Out Dil | 17.1M | 17.1M |